全文获取类型
收费全文 | 16215篇 |
免费 | 1002篇 |
国内免费 | 235篇 |
专业分类
耳鼻咽喉 | 384篇 |
儿科学 | 237篇 |
妇产科学 | 291篇 |
基础医学 | 2753篇 |
口腔科学 | 305篇 |
临床医学 | 1299篇 |
内科学 | 3274篇 |
皮肤病学 | 458篇 |
神经病学 | 1204篇 |
特种医学 | 1186篇 |
外科学 | 2105篇 |
综合类 | 95篇 |
现状与发展 | 3篇 |
一般理论 | 10篇 |
预防医学 | 612篇 |
眼科学 | 433篇 |
药学 | 1306篇 |
中国医学 | 156篇 |
肿瘤学 | 1341篇 |
出版年
2024年 | 12篇 |
2023年 | 135篇 |
2022年 | 371篇 |
2021年 | 665篇 |
2020年 | 271篇 |
2019年 | 441篇 |
2018年 | 528篇 |
2017年 | 416篇 |
2016年 | 614篇 |
2015年 | 891篇 |
2014年 | 966篇 |
2013年 | 1059篇 |
2012年 | 1584篇 |
2011年 | 1430篇 |
2010年 | 866篇 |
2009年 | 730篇 |
2008年 | 901篇 |
2007年 | 952篇 |
2006年 | 781篇 |
2005年 | 631篇 |
2004年 | 525篇 |
2003年 | 470篇 |
2002年 | 396篇 |
2001年 | 309篇 |
2000年 | 243篇 |
1999年 | 183篇 |
1998年 | 115篇 |
1997年 | 101篇 |
1996年 | 89篇 |
1995年 | 66篇 |
1994年 | 55篇 |
1993年 | 50篇 |
1992年 | 47篇 |
1991年 | 50篇 |
1990年 | 42篇 |
1989年 | 69篇 |
1988年 | 55篇 |
1987年 | 53篇 |
1986年 | 38篇 |
1985年 | 30篇 |
1984年 | 24篇 |
1983年 | 16篇 |
1982年 | 21篇 |
1981年 | 25篇 |
1980年 | 21篇 |
1979年 | 18篇 |
1978年 | 15篇 |
1977年 | 15篇 |
1976年 | 16篇 |
1975年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
The diabetogenic capacity of the M-variant of encephalomyocarditis (EMC) virus was markedly diminished after passage in mouse kidney cell cultures. One passage in mice fully restored this capacity. Virus harvested after five passages in either susceptible (SWR/J) or resistant (C57BL/6J) strains of mice was capable of producing diabetes in susceptible SWR/J mice but not in resistant C57BL/6J mice. Resistance was not overcome by inoculating mice with high concentrations of virus. Immunofluorescence studies showed that islets from strains of mice (i.e. CBA, AKR, C57BL/6J, A/J) that did not develop diabetes after infection with EMC virus, nonetheless, contained virus antigens. The percentage of cells in the islets containing virus antigens varied from 3-6% in CBA to 13-5% in A/J. In contrast 38% of the islet cells in susceptible SWR/J mice contained virus antigens. It is concluded that both the genetic background of the host and the passage history of the virus influence the development of diabetes. 相似文献
22.
Missing data such as appropriateness ratings in clinical research are a common problem and this often yields a biased result. This paper aims to introduce the multiple imputation method to handle missing data in clinical research and to suggest that the multiple imputation technique can give more accurate estimates than those of a complete-case analysis. The idea of multiple imputation is that each missing value is replaced with more than one plausible value. The appropriateness method was developed as a pragmatic solution to problem of trying to assess "appropriate" surgical and medical procedures for patients. Cataract surgery was selected as one of four procedures that were evaluated as a part of the Clinical Appropriateness Initiative. We created mild to high missing rates of 10%, 30% and 50% and compared the performance of logistic regression in cataract surgery. We treated the coefficients in the original data as true parameters and compared them with the other results. In the mild missing rate (10%), the deviation from the true coefficients was quite small and ignorable. After removing the missing data, the complete-case analysis did not reveal any serious bias. However, as the missing rate increased, the bias was not ignorable and it distorted the result. This simulation study suggests that a multiple imputation technique can give more accurate estimates than those of a complete-case analysis, especially for moderate to high missing rates (30 - 50%). In addition, the multiple imputation technique yields better accuracy than a single imputation technique. Therefore, multiple imputation is useful and efficient for a situation in clinical research where there is large amounts of missing data. 相似文献
23.
Lee Lucy Eunju Pyo Jung Yoon Ahn Sung Soo Song Jason Jungsik Park Yong-Beom Lee Sang-Won 《International urology and nephrology》2021,53(8):1631-1638
International Urology and Nephrology - A systemic inflammation response index (SIRI) has been recently introduced as a tool for the assessment of the prognosis of several critical medical... 相似文献
24.
Jun Ho Kim Eunsun Oh Young Cheol Yoon Do Kyung Lee Sung-Sahn Lee Joon Ho Wang 《Arthroscopy》2021,37(1):209-221
25.
26.
Raoud Marayati Laura V. Bownes Colin H. Quinn Nikita Wadhwani Adele P. Williams Hooper R. Markert Venkatram Atigadda Jamie M. Aye Jerry E. Stewart Karina J. Yoon Elizabeth A. Beierle 《Journal of pediatric surgery》2021,56(6):1165-1173
IntroductionThe poor therapeutic efficacy seen with current treatments for neuroblastoma may be attributed to stem cell-like cancer cells (SCLCCs), a subpopulation of cancer cells associated with poor prognosis and disease recurrence. Retinoic acid (RA) is a differentiating agent used as maintenance therapy for high-risk neuroblastoma but nearly half of children treated with RA relapse. We hypothesized that 6-Methyl-UAB30 (6-Me), a second-generation rexinoid recently developed with a favorable toxicity profile compared to RA, would reduce cancer cell stemness in human neuroblastoma patient-derived xenografts (PDXs).MethodsCells from three neuroblastoma PDXs were treated with 6-Me and proliferation, viability, motility, and cell-cycle progression were assessed. CD133 expression, sphere formation, and mRNA abundance of stemness and differentiation markers were evaluated using flow cytometry, in vitro extreme limiting dilution analysis, and real-time PCR, respectively.ResultsTreatment with 6-Me decreased proliferation, viability, and motility, and induced cell-cycle arrest and differentiation in all three neuroblastoma PDXs. In addition, 6-Me treatment led to decreased CD133 expression, decreased sphere-forming ability, and decreased mRNA abundance of Oct4, Nanog, and Sox2, indicating decreased cancer cell stemness.Conclusions6-Me decreased oncogenicity and reduced cancer cell stemness of neuroblastoma PDXs, warranting further exploration of 6-Me as potential novel therapy for neuroblastoma. 相似文献
27.
Sara Kim Berik Rovgaliyev Jeong-Moo Lee Kwang-Woong Lee Suk Kyun Hong Jae-Hyung Cho Kyung Chul Yoon Nam-Joon Yi Kyung-Suk Suh 《Transplantation proceedings》2021,53(1):200-206
BackgroundSeveral studies have reported that solid organ transplant recipients have a high risk for malignant tumors because the suppressed immune system fails in preventing malignant transformations. De novo malignancy after transplantation is the most common cause of death in the late period after liver transplant (LT). This study investigated the clinical significance of de novo malignancy after LT, and it is the largest study based in Korea to report long-term follow-up results associated with de novo malignancy after LT.MethodsData of 1793 adults who underwent LT in Seoul National University Hospital were retrospectively collected, and medical charts and data from the Ministry of Public Administration and Security were reviewed to examine the causes of death and de novo malignancy status. The Fisher exact test and Kaplan-Meier survival analysis were used to analyze the data.ResultsOf the 1793 recipients, 27 died of de novo malignancies. Of 875 hepatocellular carcinoma (HCC) patients, 12 died, and of 918 non-HCC patients, 15 died. De novo malignancy was the main cause of death at 5 years after LT but was not in the initial 5 years. In Korea the most common cancers that developed after LT were gastric cancer (21.4%) and lymphoma (14.3%). De novo HCC in non-HCC cases was found in 2 patients.ConclusionDe novo malignancy is a key factor affecting long-term survival after LT. Therefore, regular screening and education are important for improving long-term survival and quality of life in these patients after LT. 相似文献
28.
29.
30.
Pil Whan Yoon Jong Yeal Kang Chul-Ho Kim Soong Joon Lee Jeong Joon Yoo Hee Joong Kim Sung Keun Kang Ju Hyeon Min Kang Sup Yoon 《Clinics in Orthopedic Surgery》2021,13(1):37
BackgroudOutcomes of traditional treatment for osteonecrosis of the femoral head (ONFH) are not always satisfactory. Hence, cell-supplementation therapy has been attempted to facilitate necrotic-tissue regeneration. Adipose-derived mesenchymal stem cell (ADMSC) transplantation is potentially advantageous over bone marrow-derived MSC implantation, but its outcomes for ONFH remain unclear. The aim of this study was to determine 2-year radiological and clinical outcomes of culture-expanded autologous ADMSC implantation for ONFH.MethodsEighteen hips with necrotic lesions involving ≥ 30% of the femoral head were included. ADMSCs were harvested by liposuction and culture expanded for 3 passages over 3 weeks. With a 6-mm single drilling, ADMSCs were implanted into the necrotic zone. All patients underwent magnetic resonance imaging (MRI), single-photon emission computed tomography/computed tomography (SPECT/CT) at screening and 6 months, 12 months, and 24 months postoperatively. The primary outcome was the change in the size of necrotic area on MRI. Secondary outcomes were changes in clinical scores and radioisotope uptake on SPECT/CT. Conversion total hip arthroplasty (THA) was defined as the endpoint.ResultsPreoperatively, the necrotic lesion extent was 63.0% (38.4%–96.7%) of the femoral head. The mean Harris hip score was 89.2, the University of California at Los Angeles (UCLA) score was 5.6, and Western Ontario and McMaster Universities Arthritis index (WOMAC) was 79.4. Three patients underwent THA and 1 patient died in an accident. Finally, 11 patients (14 hips) were available for ≥ 2-year follow-up. At the last follow-up, no surgery-related complications occurred, and 14 of 17 hips (82%) were able to perform daily activities without THA requirement. There was no significant decrease in lesion size between any 2 intervals on MRI. However, widening of high signal intensity bands on T2-weighted images inside the necrotic lesion was observed in 9 of 14 hips (64%); 11 of 14 hips (79%) showed increased vascularity on SPECT/CT at 2 years postoperatively. No significant differences were observed between preoperative and 24-month mean Harris hip score (89.2 vs. 88.6), WOMAC (79.4 vs. 75.7), and UCLA score (5.6 vs. 6.2).ConclusionsOur outcomes suggest that culture-expanded ADMSC implantation is a viable option for ONFH treatment without adverse events. 相似文献